STOCK TITAN

Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has filed its 2022 Universal Registration Document with the AMF and its annual report on Form 20-F with the SEC for the year ending December 31, 2022. These filings provide comprehensive insights into the company's operations and financial performance. The Universal Registration Document can be accessed via AMF's website, and the Form 20-F is available on the SEC's website. Innate Pharma is developing innovative immunotherapies, leveraging its proprietary ANKET platform. Its lead program, lacutamab, targets advanced forms of cutaneous and peripheral T cell lymphomas, while collaborating with partners like AstraZeneca.

Positive
  • Filed 2022 Universal Registration Document with AMF and SEC.
  • Development of innovative immunotherapies through proprietary ANKET platform.
  • Partnerships with major biopharmaceutical companies like AstraZeneca.
Negative
  • None.

MARSEILLE, France--(BUSINESS WIRE)-- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2022 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 6, 2023. It can be downloaded (in French) on the Company’s website and on the AMF’s website.

The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2022 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company’s website and on the SEC’s website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn.

Information about Innate Pharma shares

ISIN code
Ticker code
LEI

 

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

What is the significance of Innate Pharma's filing of its 2022 Universal Registration Document?

The filing provides crucial insights into Innate Pharma's operations and financials for the year 2022.

When did Innate Pharma file its annual report on Form 20-F with the SEC?

Innate Pharma filed its annual report on Form 20-F with the SEC on April 6, 2023.

What are the key programs developed by Innate Pharma?

Innate Pharma's key programs include lacutamab for lymphomas and monalizumab for lung cancer.

Which companies does Innate Pharma partner with for its development efforts?

Innate Pharma collaborates with biopharmaceutical leaders like Sanofi and AstraZeneca.

Innate Pharma S.A. ADS

NASDAQ:IPHA

IPHA Rankings

IPHA Latest News

IPHA Stock Data

170.53M
80.95M
0.5%
0.08%
Biotechnology
Healthcare
Link
United States of America
Marseille